10x Genomics (TXG) Current Deferred Revenue (2018 - 2026)

10x Genomics (TXG) has 9 years of Current Deferred Revenue data on file, last reported at $24.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 27.38% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (down 27.38% YoY), and the FY2025 full-year result was $34.4 million, up 3.71% from the prior year.
• Current Deferred Revenue declined to $24.3 million in Q1 2026, from $34.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $34.4 million in Q4 2025 to a low of $6.5 million in Q2 2022.
• A 5-year average of $19.6 million and a median of $21.4 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 201.62% in 2024 and decreased 27.38% in 2026, its largest moves.
• Tracing TXG's Current Deferred Revenue over 5 years: stood at $11.0 million in 2022, then soared by 99.09% to $22.0 million in 2023, then soared by 51.02% to $33.2 million in 2024, then increased by 3.71% to $34.4 million in 2025, then declined by 29.24% to $24.3 million in 2026.
• Business Quant data shows TXG's Current Deferred Revenue at $24.3 million in Q1 2026, $34.4 million in Q4 2025, and $22.1 million in Q3 2025.